Literature DB >> 28159600

Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.

Karlyn A Martin1, Craig R Lee2, Timothy M Farrell3, Stephan Moll4.   

Abstract

Bariatric surgery may alter the absorption, distribution, metabolism, or elimination (disposition) of orally administered drugs via changes to the gastrointestinal tract anatomy, body weight, and adipose tissue composition. As some patients who have undergone bariatric surgery will need therapeutic anticoagulation for various indications, appropriate knowledge is needed regarding anticoagulant drug disposition and resulting efficacy and safety in this population. We review general considerations about oral drug disposition in patients after bariatric surgery, as well as existing literature on oral anticoagulation after bariatric surgery. Overall, available evidence on therapeutic anticoagulation is very limited, and individual drug studies are necessary to learn how to safely and effectively use the direct oral anticoagulants. Given the sparsity of currently available data, it appears most prudent to use warfarin with international normalized ratio monitoring, and not direct oral anticoagulants, when full-dose anticoagulation is needed after bariatric surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Absorption; Anticoagulation; Apixaban; Bariatric surgery; Biliopancreatic diversion; Bleeding; Dabigatran; Edoxaban; Efficacy; Gastrectomy; Gastric banding; Obesity; Pharmacokinetics; Rivaroxaban; Roux-en-Y; Safety; Thrombosis; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28159600      PMCID: PMC5401640          DOI: 10.1016/j.amjmed.2016.12.033

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  44 in total

Review 1.  Pharmacokinetic effects of bariatric surgery.

Authors:  Allan Edwards; Mary H H Ensom
Journal:  Ann Pharmacother       Date:  2011-12-20       Impact factor: 3.154

Review 2.  Altered drug disposition following bariatric surgery: a research challenge.

Authors:  H Karl Greenblatt; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

3.  Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.

Authors:  Joachim Stangier; Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Gerhard Nehmiz; Hildegard Stähle; Karin Rathgen; Robbyna Svärd
Journal:  J Clin Pharmacol       Date:  2005-05       Impact factor: 3.126

Review 4.  The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Authors:  Leslie Z Benet
Journal:  J Pharm Sci       Date:  2012-11-12       Impact factor: 3.534

5.  Warfarin absorption after massive small bowel resection.

Authors:  D M Lutomski; R J LaFrance; R H Bower; J E Fischer
Journal:  Am J Gastroenterol       Date:  1985-02       Impact factor: 10.864

6.  The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study.

Authors:  Lieke Mitrov-Winkelmolen; Marie-Christine W van Buul-Gast; Dingeman J Swank; Hans W P M Overdiek; Ron H N van Schaik; Daan J Touw
Journal:  Obes Surg       Date:  2016-09       Impact factor: 4.129

7.  Warfarin users prone to coagulopathy in first 30 days after hospital discharge from gastric bypass.

Authors:  Peter Bechtel; Richard Boorse; Peter Rovito; T Daniel Harrison; John Hong
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

8.  Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy.

Authors:  Diana M Sobieraj; Fei Wang; Orlando C Kirton
Journal:  Pharmacotherapy       Date:  2008-12       Impact factor: 4.705

Review 9.  Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.

Authors:  Wolfgang Mueck; Jan Stampfuss; Dagmar Kubitza; Michael Becka
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 10.  Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Authors:  Dolly A Parasrampuria; Kenneth E Truitt
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

View more
  14 in total

Review 1. 

Authors:  Sabrina Lorico; Blaine Colton
Journal:  Can Fam Physician       Date:  2020-06       Impact factor: 3.275

2.  Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.

Authors:  Deborah DeCamillo; Brian Haymart; Geoffrey D Barnes
Journal:  J Thromb Thrombolysis       Date:  2021-09-24       Impact factor: 2.300

3.  Bariatric Surgery in Patients on Chronic Anticoagulation Therapy.

Authors:  Gautam Sharma; Zubaidah Nor Hanipah; Ali Aminian; Suriya Punchai; Emre Bucak; Philip R Schauer; Stacy A Brethauer
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

4.  Prophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portomesenteric venous thrombosis.

Authors:  J I Rodríguez; V Kobus; I Téllez; G Pérez
Journal:  Ann R Coll Surg Engl       Date:  2020-09-24       Impact factor: 1.891

Review 5.  Medication management and pharmacokinetic changes after bariatric surgery.

Authors:  Sabrina Lorico; Blaine Colton
Journal:  Can Fam Physician       Date:  2020-06       Impact factor: 3.275

6.  Effect of Laparoscopic Sleeve Gastrectomy on Heart Transplant Status in 4 Patients with Left Ventricular Assist Devices.

Authors:  Christopher T Ryan; Adriana Santiago; Nabil Tariq; Harveen K Lamba
Journal:  Tex Heart Inst J       Date:  2020-08-01

Review 7.  Oral drug dosing following bariatric surgery: General concepts and specific dosing advice.

Authors:  Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2021-06-03       Impact factor: 3.716

8.  A case report of recurrent transient ischaemic attacks on dabigatran for atrial fibrillation: real-world insight into treatment failure.

Authors:  Ronald Huynh; Stephanie Anderson; Vivien M Chen; Thomas Yeoh
Journal:  Eur Heart J Case Rep       Date:  2020-03-03

Review 9.  Cancer and Thrombosis: New Treatments, New Challenges.

Authors:  Anders Erik Astrup Dahm
Journal:  Med Sci (Basel)       Date:  2021-06-03

Review 10.  How I treat cancer-associated thrombosis.

Authors:  Florian Moik; Ingrid Pabinger; Cihan Ay
Journal:  ESMO Open       Date:  2020-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.